Cargando…

Indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial

BACKGROUND: D3 lymph node dissection is recommended for patients with advanced sigmoid and rectal cancer in Japan. This trial aimed to investigate the feasibility of indocyanine green (ICG) as a tracer to increase the nodal harvest during D3 lymph node dissection in patients with sigmoid and rectal...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Jinliang, Wang, Shijie, Yan, Botao, Tang, Yuting, Zheng, Jixiang, Ji, Hongli, Hu, Yaowen, Zhuang, Baoxiong, Deng, Haijun, Yan, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897192/
https://www.ncbi.nlm.nih.gov/pubmed/36515673
http://dx.doi.org/10.1093/bjsopen/zrac151
_version_ 1784882200941953024
author Wan, Jinliang
Wang, Shijie
Yan, Botao
Tang, Yuting
Zheng, Jixiang
Ji, Hongli
Hu, Yaowen
Zhuang, Baoxiong
Deng, Haijun
Yan, Jun
author_facet Wan, Jinliang
Wang, Shijie
Yan, Botao
Tang, Yuting
Zheng, Jixiang
Ji, Hongli
Hu, Yaowen
Zhuang, Baoxiong
Deng, Haijun
Yan, Jun
author_sort Wan, Jinliang
collection PubMed
description BACKGROUND: D3 lymph node dissection is recommended for patients with advanced sigmoid and rectal cancer in Japan. This trial aimed to investigate the feasibility of indocyanine green (ICG) as a tracer to increase the nodal harvest during D3 lymph node dissection in patients with sigmoid and rectal cancer. METHODS: This prospective randomized clinical trial was performed between May 2021 and April 2022. The inclusion criteria were patients with stage I–III sigmoid or rectal cancer eligible for laparoscopic resection. Patients were 1: 1 randomized to either the ICG group (endoscopic ICG injection at the tumour site and intraoperative imaging to guide dissection) or the control group (routine laparoscopic white-light imaging). All patients were treated with D3 dissection, and the primary outcome was the number of harvested lymph nodes at the D3 level. RESULTS: Out of 210 patients screened, a total of 66 patients were enrolled and randomized. Patients in the two groups presented similar ages and clinical stages (ICG group versus control group, median age of 58.0 versus 58.5 years; stage III 36.4 per cent versus 36.4 per cent, whereas the rate of rectal cancer was 27.3 per cent versus 48.5 per cent respectively). ICG imaging was helpful for completely dissecting D3 lymph nodes and could identify a median of more than 2 (range 1–6) D3 lymph nodes neglected by routine laparoscopic white-light imaging during surgery. The median number of D3 lymph nodes harvested in the ICG group was significantly higher than that in the control group (7.0 versus 5.0, P = 0.003); however, there was no significant difference in the median numbers of positive D1, D2, and D3 lymph nodes between the two groups. CONCLUSION: ICG is safe and feasible to guide D3 lymph node dissection and can increase the number of harvested D3 lymph nodes in patients with sigmoid and rectal cancer. Registration number: NCT04848311 (http://www.clinicaltrials.gov).
format Online
Article
Text
id pubmed-9897192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98971922023-02-06 Indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial Wan, Jinliang Wang, Shijie Yan, Botao Tang, Yuting Zheng, Jixiang Ji, Hongli Hu, Yaowen Zhuang, Baoxiong Deng, Haijun Yan, Jun BJS Open Randomized Clinical Trial BACKGROUND: D3 lymph node dissection is recommended for patients with advanced sigmoid and rectal cancer in Japan. This trial aimed to investigate the feasibility of indocyanine green (ICG) as a tracer to increase the nodal harvest during D3 lymph node dissection in patients with sigmoid and rectal cancer. METHODS: This prospective randomized clinical trial was performed between May 2021 and April 2022. The inclusion criteria were patients with stage I–III sigmoid or rectal cancer eligible for laparoscopic resection. Patients were 1: 1 randomized to either the ICG group (endoscopic ICG injection at the tumour site and intraoperative imaging to guide dissection) or the control group (routine laparoscopic white-light imaging). All patients were treated with D3 dissection, and the primary outcome was the number of harvested lymph nodes at the D3 level. RESULTS: Out of 210 patients screened, a total of 66 patients were enrolled and randomized. Patients in the two groups presented similar ages and clinical stages (ICG group versus control group, median age of 58.0 versus 58.5 years; stage III 36.4 per cent versus 36.4 per cent, whereas the rate of rectal cancer was 27.3 per cent versus 48.5 per cent respectively). ICG imaging was helpful for completely dissecting D3 lymph nodes and could identify a median of more than 2 (range 1–6) D3 lymph nodes neglected by routine laparoscopic white-light imaging during surgery. The median number of D3 lymph nodes harvested in the ICG group was significantly higher than that in the control group (7.0 versus 5.0, P = 0.003); however, there was no significant difference in the median numbers of positive D1, D2, and D3 lymph nodes between the two groups. CONCLUSION: ICG is safe and feasible to guide D3 lymph node dissection and can increase the number of harvested D3 lymph nodes in patients with sigmoid and rectal cancer. Registration number: NCT04848311 (http://www.clinicaltrials.gov). Oxford University Press 2022-12-14 /pmc/articles/PMC9897192/ /pubmed/36515673 http://dx.doi.org/10.1093/bjsopen/zrac151 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Randomized Clinical Trial
Wan, Jinliang
Wang, Shijie
Yan, Botao
Tang, Yuting
Zheng, Jixiang
Ji, Hongli
Hu, Yaowen
Zhuang, Baoxiong
Deng, Haijun
Yan, Jun
Indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial
title Indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial
title_full Indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial
title_fullStr Indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial
title_full_unstemmed Indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial
title_short Indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial
title_sort indocyanine green for radical lymph node dissection in patients with sigmoid and rectal cancer: randomized clinical trial
topic Randomized Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897192/
https://www.ncbi.nlm.nih.gov/pubmed/36515673
http://dx.doi.org/10.1093/bjsopen/zrac151
work_keys_str_mv AT wanjinliang indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial
AT wangshijie indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial
AT yanbotao indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial
AT tangyuting indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial
AT zhengjixiang indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial
AT jihongli indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial
AT huyaowen indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial
AT zhuangbaoxiong indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial
AT denghaijun indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial
AT yanjun indocyaninegreenforradicallymphnodedissectioninpatientswithsigmoidandrectalcancerrandomizedclinicaltrial